InterShunt is developing a proprietary catheter system that allows for the capture and excision of tissue from the interatrial septum. The result is a left to right atrial shunt that off-loads elevated left atrial pressure, reducing symptoms in Heart Failure patients. The mechanical system is designed for safety and ease of use and is the only interatrial shunting device that requires no implant and no energy.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/11/21 | undisclosed |
Arsenal Capital Management Solas Bioventures  | undisclosed |
